These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9714071)

  • 1. Hypothesis: multiple sclerosis is a type I interferon deficiency syndrome.
    Brod SA
    Proc Soc Exp Biol Med; 1998 Sep; 218(4):278-83. PubMed ID: 9714071
    [No Abstract]   [Full Text] [Related]  

  • 2. Absence of immunoreactive interferon-alpha in CSF from patients with multiple sclerosis.
    Abbott RJ; Giles PD; Bolderson I
    J Neurol Neurosurg Psychiatry; 1986 Jan; 49(1):102-3. PubMed ID: 3958724
    [No Abstract]   [Full Text] [Related]  

  • 3. Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy.
    Verweij CL; Vosslamber S
    Discov Med; 2013 Jan; 15(80):51-60. PubMed ID: 23375014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type I IFN via the GALT system.
    Brod SA
    J Interferon Cytokine Res; 1999 Aug; 19(8):841-52. PubMed ID: 10476927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of binding anti-IFNbeta antibodies in IFNbeta-treated MS patients: lessons for the clinician and basic scientist.
    Pachner AR
    J Neuroimmunol; 2008 Feb; 194(1-2):5-6. PubMed ID: 18031830
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis.
    Bagnato F; Pozzilli C
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1153-63. PubMed ID: 12831350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interferon-producing and cytotoxic activity of natural killer cells in multiple sclerosis patients].
    Sorokin AM; Koval'chuk LV; Tunkel' OI; Cheknev SB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(2):211-5. PubMed ID: 2437743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoregulatory properties of type-I interferons: relevance to multiple sclerosis and the hypereosinophilic syndrome.
    Bartholomé EJ; Roufosse FE
    Acta Clin Belg; 1997; 52(6):350-9. PubMed ID: 9489130
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: A milestone in multiple sclerosis.
    Lancet; 1976 Feb; 1(7957):459-60. PubMed ID: 55723
    [No Abstract]   [Full Text] [Related]  

  • 10. [Multifactorial pathogenesis and immunoendocrine modulation of multiple sclerosis].
    Akimov GA; Golovkin VI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1987; 87(2):199-203. PubMed ID: 3577506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferon production in multiple sclerosis].
    Khaletskaia EV; Fadeeva LL; Selezneva AIu; Priĭmiagi LS; Luka VIa
    Vopr Virusol; 1981; (2):218-21. PubMed ID: 6168116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multiple sclerosis as a sequela of measles?].
    Panelius M; Salmi AA
    Fortschr Med; 1972 May; 90(14):555-6. PubMed ID: 5072276
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients.
    Pentón-Rol G; Cervantes-Llanos M; Cabrera-Gómez JA; Alonso-Ramírez R; Valenzuela-Silva C; Rodríguez-Lara R; Montero-Casimiro E; Bello-Rivero I; López-Saura P
    Int Immunopharmacol; 2008 Jun; 8(6):881-6. PubMed ID: 18442793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Destruction of nerve cells cultured "in vitro" by lymphocytes from patients with multiple sclerosis. Auto-immune pathogenesis of multiple sclerosis].
    Halpern B; Bakouche P; Martial-Lasfargues C
    Presse Med (1893); 1969 Dec; 77(55):2103-6. PubMed ID: 4190510
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon beta in multiple sclerosis: is IL-12 suppression the key?
    Karp CL; Biron CA; Irani DN
    Immunol Today; 2000 Jan; 21(1):24-8. PubMed ID: 10637555
    [No Abstract]   [Full Text] [Related]  

  • 16. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis.
    Comabella M; Lünemann JD; Río J; Sánchez A; López C; Julià E; Fernández M; Nonell L; Camiña-Tato M; Deisenhammer F; Caballero E; Tortola MT; Prinz M; Montalban X; Martin R
    Brain; 2009 Dec; 132(Pt 12):3353-65. PubMed ID: 19741051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of multiple sclerosis: in search for a personalized therapy.
    Martinez-Forero I; Pelaez A; Villoslada P
    Expert Opin Pharmacother; 2008 Dec; 9(17):3053-67. PubMed ID: 19006478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of multiple sclerosis with various interferons: the cons.
    Johnson KP
    Neurology; 1988 Jul; 38(7 Suppl 2):62-5. PubMed ID: 3133576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon therapy in multiple sclerosis. Mechanism of action, side effects, results].
    Huber M
    Nervenarzt; 1988 Sep; 59(9):514-20. PubMed ID: 2460777
    [No Abstract]   [Full Text] [Related]  

  • 20. [Changes of proteins and their complexes in the serum and liquor in disseminated cerebrospinal sclerosis].
    Vymazal J
    Cas Lek Cesk; 1968 Nov; 107(47):1422-5. PubMed ID: 5696567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.